Glass House Brands (GLAS) Research & Development (2020 - 2026)
Glass House Brands' (GLAS) quarterly Research & Development came in at $529000.0 in Q1 2026, up 11.13% on a QoQ basis from $476000.0 in Q4 2025.
Glass House Brands (GLAS) Research & Development (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has 7 years of Research & Development data on file, last reported at $529000.0 in Q1 2026.
- On a quarterly basis, Research & Development changed N/A year-over-year to $529000.0 in Q1 2026; TTM through Mar 2026 was $2.5 million, a N/A change from a year earlier, with the FY2025 full-year figure at $2.7 million, up 10.38% from the prior year.
- Research & Development for Q1 2026 stood at $529000.0, up from $476000.0 in the prior quarter.
- Over the last five years, Research & Development for GLAS reached as high as $997000.0 in Q2 2023 and fell as low as $476000.0 in Q4 2025.
- Historically, Research & Development has averaged $761711.6 across 5 years, with a median of $803678.0 in 2022.
- Across the five-year window, Research & Development surged 77.22% in 2022 and slumped 31.59% in 2024, its largest moves.
- Year by year, Research & Development stood at $859000.0 in 2022, then increased by 16.07% to $997000.0 in 2023, then slumped by 31.59% to $682000.0 in 2024, then tumbled by 30.21% to $476000.0 in 2025, then grew by 11.13% to $529000.0 in 2026.
- Per Business Quant data, the three most recent Research & Development figures were $529000.0 in Q1 2026, $476000.0 in Q4 2025, and $703000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 696.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 180.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 7.37 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 138.20 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 248.60 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 296.20 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 97.00 Mn |
| 10 | Glass House Brands | 873.84 Mn | 845.91 Mn | 10.02 Mn | 529,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 529,000.00 |
| Dec 31, 2025 | 476,000.00 |
| Sep 30, 2025 | 703,000.00 |
| Jun 30, 2025 | 803,000.00 |
| Jun 30, 2024 | 682,000.00 |
| Jun 30, 2023 | 997,000.00 |
| Dec 31, 2022 | 859,000.00 |
| Sep 30, 2022 | 804,356.00 |
| Jun 30, 2022 | 898,000.00 |
| Mar 31, 2022 | 865,760.00 |
| Dec 31, 2021 | 1.18 Mn |
| Sep 30, 2021 | 857,000.00 |
| Jun 30, 2021 | 1.01 Mn |
| Mar 31, 2021 | 488,535.00 |
| Dec 31, 2020 | 371.35 Bn |
| Sep 30, 2020 | 336,730.00 |
| Mar 31, 2020 | 354,425.00 |